

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn et al.
		Art Unit	1647
		Examiner Name	Regina M. DeBerry
Sheet	2	of	6
		Attorney Docket Number	M0351-287806

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	BABAN et al., "A Minor Population of Splenic Dendritic Cells Expressing CD19 Mediates IDO-Dependent T Cell Suppression Via Type 1 IFN Signaling Following B7 Ligation," <i>International Immunology</i> , 2005 17(7): 909-919	
	7	BJORCK et al., "Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice" <i>Blood</i> , 2001, 98(13): 3520-3526.	
	8	BORRAS et al., "Identification of Both Myeloid CD11c and Lymphoid CD11c Dendritic Cell Subsets in Cord Blood," <i>British Journal of Haematology</i> , 2001, 113: 925-931.	
	9	CADY et al., "1-Methyl-DL-tryptophan, beta-(3-benzoxalanil)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzobithienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase," <i>Archives of Biochemistry and Biophysics</i> , 1991, 291(2): 326-333 (Abstract)	
	10	CHAPMAN et al., "Pharmacologically active benzo[b]thiophene derivatives. VIII Benzo[b]thiophene analogs of tryptophan and alpha-methyltryptophan, and some of their 5-substituted derivatives," <i>Journal of the Chemical Society, Section C: Organic Chemistry</i> , 1969, No. 14: 1855-1858 (Abstract)	
	11	DÄGHER et al., "Pilot Trial of Tumor-Specific Peptide Vaccination and Continuous Infusion Interleukin-2 in Patients with Recurrent Ewing Sarcoma and Alveolar Rhabdomyosarcoma: An Inter-Institute NIH Study," <i>Med. Pediatr. Oncol.</i> 2000; 36: 6A-12	
	12	European Patent Office, Supplementary Partial European Search Report, Application No. EP 02 80 7233, Date of Completion of the Search October 19, 2005, 5 pages.	
	13	FRIBERG et al., "Indoleamine 2,3-Dioxygenase Contributes to Tumor Cell Evasion of T Cell-Mediated Rejection," <i>Int. J. Cancer</i> , 2002, 101: 151-155.	
	14	FRIBERG et al., "Indoleamine 2,3-dioxygenase (IDO) protects established tumors from T cell mediated rejection," <i>Proc. Amer. Ass. Cancer Res. Ann. Meet.</i> , 2000, No. 714, page 112 (Abstract)	
	15	FRUMENTO et al., "Inhibition of T cell proliferation by the purified enzyme indoleamine 2,3-dioxygenase," <i>Human Immunology, The European Federation for Immunogenetics 14<sup>th</sup> Annual Conference, April 4-7, 2000</i> , 61, page S140 (Abstract)	
	16	GRÖHMANN et al., "IFN-γ Inhibits Presentation of a Tumor-Self Peptide by CD8α <sup>+</sup> Dendritic Cells Via Potentiation of the CD8α <sup>+</sup> subset" <i>Journal of Immunology</i> , 2000, 165(3): 1357-1363.	
	17	HWU et al., "Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation" <i>J. Immunol.</i> , 2000, 164: 3596-3599	
	18	International Search Report for PCT/US02/11319, filed April 12, 2002 mailed September 6, 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 \* Applicant's unique citation designation number (optional). \* Applicant to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

### Complete if Known

Application Number	10/680,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn et al.
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	M0351-287806

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	19	LEE et al., "Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma," <i>Laboratory Investigation</i> , 2003, <u>83</u> (10): 1457-1466.	
	20	MELLOR et al., "Extinguishing Maternal Immune Responses during Pregnancy: Implications for Immunosuppression," <i>Seminars in Immunology</i> , 2001, <u>13</u> (4): 213-218.	
	21	MELLOR et al., "Tryptophan catabolism and T cell tolerance: immunosuppression by starvation?" <i>Immunology Today</i> , 1999, <u>20</u> : 469-473.	
	22	MELLOR et al., "Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses," <i>J. Reprod. Immunol.</i> , 2001, <u>52</u> (1-2): 5-13.	
	23	MELLOR et al., "M.A.G. transgenic mice," <i>J. Reprod. Immunol.</i> , 1999, <u>43</u> : 253-261.	
	24	MELLOR et al., "Immunology at the maternal-fetal interface," <i>Ann. Rev. Immunol.</i> , 2000, <u>18</u> : 367-391.	
	25	MELLOR et al., "IDO expression by dendritic cells: tolerance and tryptophan catabolism" <i>Nat. Immunol. Rev.</i> , 2004, <u>4</u> : 762-774	
		<b>DUPLICATE</b>	
	26	MUNN et al., "Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells," <i>Journal of Immunology</i> , 2004, <u>172</u> : 4100-4110.	
	27	MUNN et al., "Dendritic Cells Have the Option to Express IDO-Mediated Suppression or Not," <i>Blood</i> , 2005, <u>105</u> (6): 2618.	
	28	MUNN et al., "Macrophage inhibition of T cell activation via depletion of tryptophan," <i>Blood</i> , 1998, <u>48</u> : IV (Abstract).	
	29	MUNN et al., "Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase," <i>Science</i> , 2002, <u>297</u> : 1867-1870.	
	30	MUNN et al., "Regulation of T cell activation by macrophage (Mvariant pin)-mediated tryptophan (TRP) depletion," <i>FASEB Journal</i> , 1998, <u>12</u> : page A276 (Abstract).	
	31	MUNN et al., "Tolerogenic Antigen-Presenting Cells," <i>Ann. NY. Acad. Sci.</i> , 2002 <u>961</u> : 343-345.	
	32	OSUGI et al., "Myeloid Blood CD11c+ Dendritic Cells and Monocyte-Derived Dendritic Cells Differ in their Ability to Stimulate T Lymphocytes," <i>Blood</i> , 2002, <u>100</u> (8): 2898-2898.	
	33	PACANOWSKI et al., "Reduced blood CD123 <sup>+</sup> (lymphoid) and CD11c <sup>+</sup> (myeloid) dendritic cell numbers in primary HIV-1 infection," <i>Blood</i> , 2001, <u>98</u> (10): 3016-3021.	

Examiner  
Signature

Date  
Considered

<sup>1</sup>EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with first communication to applicant.  
<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.